Earnings summaries and quarterly performance for AbCellera Biologics.
Executive leadership at AbCellera Biologics.
Board of directors at AbCellera Biologics.
Research analysts who have asked questions during AbCellera Biologics earnings calls.
MH
Malcolm Hoffman
BMO Capital Markets
6 questions for ABCL
Also covers: ACAD, BMY, BNTX +2 more
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
5 questions for ABCL
Also covers: ABSI, ARWR, AZTA +20 more
Allison Bratzel
Piper Sandler Companies
3 questions for ABCL
Also covers: AKBA, ALXO, ARDX +7 more
SW
Stephen Willey
Stifel
3 questions for ABCL
Also covers: ABEO, CGEN, CMPX +11 more
AN
Andrea Newkirk
Goldman Sachs
2 questions for ABCL
Also covers: ALKS, ARWR, DAWN +9 more
AT
Andrea Tan
Goldman Sachs
2 questions for ABCL
Also covers: ARWR, DAWN, INSM +3 more
Faisal Khurshid
Leerink Partners
2 questions for ABCL
Also covers: ANIP, ASND, GERN +7 more
PS
Puneet Souda
Leerink Partners
2 questions for ABCL
Also covers: A, BRKR, CSTL +21 more
SD
Srikripa Devarakonda
Truist Financial Corporation
2 questions for ABCL
Also covers: ABSI, AFMD, ARVN +12 more
SW
Stephen Willey
Stifel Financial Corp.
2 questions for ABCL
Also covers: CELC, CGEN, CUE +11 more
A
Anna
Wolfe Research
1 question for ABCL
Also covers: ARVN, ATRC, CARL +5 more
Conor MacKay
BMO Capital Markets
1 question for ABCL
Also covers: AMGN, ARVN, INCY +1 more
DM
David Martin
Bloom Burton & Co.
1 question for ABCL
Also covers: AUPH
JK
Jacqueline Kisa
TD Cowen
1 question for ABCL
Also covers: DNA, OABI, OABIW
KD
Kripa Devarakonda
Truist Securities
1 question for ABCL
Also covers: ARVN, BMY, INCY +5 more
MA
Micheal Almisry Sonntag
Leerink Partners
1 question for ABCL
SD
Steve Dechert
KeyBanc Capital Markets
1 question for ABCL
Also covers: ABSI, CERT, LFMD +2 more
Recent press releases and 8-K filings for ABCL.
AbCellera Biologics Discusses Pipeline Advancement and Strategic Direction
ABCL
New Projects/Investments
Guidance Update
- AbCellera Biologics is transitioning to a biotech-focused entity, aiming for five programs in the clinic within two years, with some potentially reaching late-stage registrational trials. This includes early-stage assets like ABCL688 (autoimmune) and ABCL386 (oncology) with first-in-class potential.
- The lead program, ABCL635, for vasomotor symptoms, is expected to have Phase 2 data readout in Q3 2026. Positive results could lead to a registrational trial for menopausal VMS and a Phase 2 trial for cancer-associated VMS as early as 2027.
- For ABCL575, an OX40L inhibitor, a data update is anticipated by year-end 2026. The company plans to partner this molecule after Phase 1 data, seeking external expertise for its full development.
- AbCellera maintains a strong financial position with $700 million in cash equivalents and committed government funding and an annual run rate of just over $100 million. A new GMP facility provides strategic advantages in supply chain control, speed, and extended patent life.
7 days ago
AbCellera Biologics Updates on Clinical Pipeline and Strategic Direction
ABCL
New Projects/Investments
Guidance Update
- AbCellera has invested approximately $1 billion over 13 years to develop an end-to-end antibody discovery, development, and manufacturing platform, now focusing on advancing its own internal programs, with its first program having entered Phase II.
- The lead program, ABCL635, an NK3R inhibitor for hot flashes (VMS), is in a Phase I/II study with Phase II data expected in Q3 2026. The company anticipates comparable efficacy to existing treatments with a better safety profile and preferred monthly auto-injection dosing, planning to advance it to a registrational trial for menopausal VMS and a Phase II trial for cancer treatment-associated VMS if positive.
- The second clinical asset, ABCL575, an OX40L inhibitor for autoimmunity, is expected to have a data update by year-end 2026 and is being considered for out-licensing to a partner.
- AbCellera holds $700 million in cash equivalents and committed government funding, with an annual run rate of approximately $120 million, providing a strong financial runway for its pipeline expansion. The company aims to have five programs in the clinic within a couple of years.
7 days ago
AbCellera Discusses Clinical Pipeline Progress and Strategic Outlook
ABCL
New Projects/Investments
- AbCellera's lead compound, ABCL635, for hot flashes (VMS), is in a Phase 1/2 study with Phase 2 data expected in Q3 2026. The company aims for comparable efficacy to existing treatments with a better safety profile and preferred monthly auto-injection dosing.
- The second clinical asset, ABCL575, an OX40L inhibitor for autoimmunity, is expected to have a data update by year-end 2026. AbCellera is open to partnering this molecule after Phase 1 data.
- The company plans to have five programs in the clinic within a couple of years, including two new assets, ABCL688 (autoimmune) and ABCL386 (oncology), which are approaching Phase 1 studies.
- AbCellera has a strong financial position with $700 million in cash equivalents and committed government funding, and its new GMP facility is online, enhancing control over the supply chain and potentially extending patent life.
7 days ago
AbCellera Biologics Reports Q4 2025 Results and Pipeline Advancements
ABCL
Earnings
Guidance Update
New Projects/Investments
- AbCellera reported $75 million in revenue for the full year 2025, up from $29 million in 2024, with $36 million stemming from the settlement of patent infringement claims.
- The company maintains a strong liquidity position with approximately $700 million in available capital, comprising $560 million in cash and equivalents and $140 million in committed government funding.
- AbCellera has completed its transition to a clinical-stage biotech, with its lead program, ABCL635, now in a Phase 2 study, and anticipates a key readout in Q3 2026.
- Two new development candidates, ABCL688 and ABCL386, are in IND-enabling activities, with plans to initiate Phase 1/2 studies in 2027.
Feb 24, 2026, 10:00 PM
AbCellera Reports Full Year 2025 Financial Results and Pipeline Progress
ABCL
Earnings
Guidance Update
New Projects/Investments
- AbCellera reported $75 million in total revenue for full-year 2025, which included $36 million from settling patent infringement claims, compared to approximately $29 million in 2024. The company also reported a net loss of $146 million, or $0.49 per share, for the year.
- The company ended 2025 with approximately $700 million in available liquidity, comprising $560 million in cash and equivalents and $140 million in committed government funding.
- AbCellera has completed its transition to a clinical-stage biotech, with ABCL635 advancing into a Phase II study and ABCL575 in Phase I. Two new development candidates, ABCL688 and ABCL386, were nominated in 2025, with IND/CTA submissions and Phase I/II studies expected in 2027.
- Key clinical readouts anticipated in 2026 include Phase II data for ABCL635 in Q3 and Phase I data for ABCL575 by the end of the year.
Feb 24, 2026, 10:00 PM
AbCellera Biologics Reports Full Year 2025 Results and Pipeline Progress
ABCL
Earnings
New Projects/Investments
Guidance Update
- AbCellera reported full year 2025 revenue of $75 million, a significant increase from $29 million in 2024, primarily driven by $47 million in licensing and royalty payments, including $36 million from settling patent infringement claims.
- The company maintains a strong liquidity position with approximately $700 million available, comprising $560 million in cash and equivalents and $140 million in committed government funding.
- AbCellera has completed its transition to a clinical-stage biotech, with a focus now on pipeline development, highlighted by the anticipated Phase 2 readout for ABCL635 in Q3 2026 and the nomination of two new development candidates in 2025.
- For the full year 2025, the company reported a net loss of $146 million and a loss of $0.49 per share, with research and development expenses increasing to $187 million as it invests in its internal programs.
Feb 24, 2026, 10:00 PM
AbCellera Biologics Provides Full Year 2025 Business and Financial Update
ABCL
Earnings
New Projects/Investments
Guidance Update
- For the full year 2025, AbCellera Biologics reported a net loss of $146.4 million and ($0.49) earnings per share.
- As of December 31, 2025, the company maintained approximately $700 million in available liquidity, including $560 million in total cash, cash equivalents, and marketable securities.
- AbCellera successfully transitioned to a clinical-stage biotech in 2025, initiating Phase 1 clinical trials for ABCL635 in June 2025 and ABCL575 in July 2025, with ABCL635 progressing to Phase 2 in January 2026.
- Key priorities for 2026 include advancing the pipeline to topline data readouts for ABCL635 and ABCL575 in H2 2026 and setting up for three additional INDs in 2027.
Feb 24, 2026, 10:00 PM
AbCellera Biologics Inc. Reports Full Year 2025 Business Results
ABCL
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- AbCellera Biologics Inc. reported full year 2025 total revenue of $75.1 million, a significant increase from $28.8 million in 2024. The company generated a net loss of $146.4 million, or $(0.49) per share, for full year 2025, an improvement from a net loss of $162.9 million, or $(0.55) per share, in 2024.
- The company ended 2025 with approximately $700 million in total available liquidity, which includes $561 million in cash, cash equivalents, and marketable securities, along with $135 million in available non-dilutive government funding.
- AbCellera transitioned to a clinical-stage biotech, advancing ABCL635 into Phase 2 and ABCL575 into Phase 1 clinical trials, contributing to a cumulative total of 19 molecules in the clinic by December 31, 2025.
- For the fourth quarter of 2025, revenue was $44.9 million, primarily driven by an upfront settlement payment from patent litigation, and the net loss was $8.9 million, or $(0.03) per share.
Feb 24, 2026, 9:15 PM
AbCellera Biologics Reports Full Year 2025 Results
ABCL
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- AbCellera reported total revenue of $75.1 million for the full year 2025, a significant increase from $28.8 million in 2024, and a net loss of $146.4 million, or $(0.49) per share, an improvement from a $162.9 million net loss in 2024.
- The company ended 2025 with approximately $700 million in available liquidity, which includes $561 million in cash, cash equivalents, and marketable securities, and $135 million in non-dilutive government funding.
- AbCellera advanced two programs, ABCL635 and ABCL575, into clinical trials during 2025, and reached a cumulative total of 104 partner-initiated program starts and 19 molecules in the clinic by year-end 2025.
Feb 24, 2026, 9:05 PM
AbCellera Biologics Provides Pipeline Update and Strategic Shift at J.P. Morgan Healthcare Conference
ABCL
New Projects/Investments
Guidance Update
- AbCellera Biologics reported approximately $680 million in total liquidity as of the end of Q3 2025 and has completed significant infrastructure investments, including a new GMP manufacturing facility that began engineering runs in December 2025.
- The company has strategically shifted its business model from primarily discovery partnerships to internal pipeline development, a decision made in September 2023, focusing on creating first-in-class and highly differentiated molecules.
- Its lead asset, AbCell 635, an antibody for non-hormonal treatment of menopausal vasomotor symptoms, has advanced to Phase 2 of a Phase 1-2 study, with a significant data readout anticipated in Q3 2026.
- Other key pipeline updates include AbCell 575 in Phase 1, with a readout expected near the end of 2026, and new development candidates AbCell 386 (oncology) and AbCell 688 (autoimmune) in IND-enabling work. The company plans to nominate one additional candidate in 2026.
Jan 14, 2026, 11:45 PM
Quarterly earnings call transcripts for AbCellera Biologics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more